Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Clin J Gastroenterol. 2021 Aug;14(4):1221-1226. doi: 10.1007/s12328-021-01432-4. Epub 2021 May 13.
Hepatitis C virus reactivation (HCVr) was defined previously as an increase in HCV RNA level of ≥ 1 log IU/mL from baseline HCV RNA level after chemotherapies or immunosuppressive therapies, but HCVr during a steroid monotherapy has rarely been reported. Here we report a 75-year-old Japanese female with chronic hepatitis C (genotype 2a) who developed HCVr after the administration of prednisolone for interstitial pneumonia. She experienced alanine aminotransferase (ALT) flare with icterus, but after the tapering of prednisolone and a liver supporting therapy, levels of HCV RNA and ALT were gradually decreased. Then, she received an anti-viral therapy with sofosbuvir/ledipasvir. Although HCV relapsed 4 weeks after the therapy, a second therapy with glecaprevir/pibrentasvir was successful. This case suggests that HCVr with hepatitis flare can occur even after a steroid monotherapy, and we should pay attention to HCVr when we administer prednisolone for patients with HCV chronic infection.
丙型肝炎病毒再激活(HCVr)之前被定义为在化疗或免疫抑制治疗后,HCV RNA 水平从基线 HCV RNA 水平升高≥1 log IU/ml,但类固醇单药治疗期间 HCVr 很少见报道。在此,我们报告了一例 75 岁日本女性,患有慢性丙型肝炎(基因型 2a),在因间质性肺炎给予泼尼松龙治疗后发生 HCVr。她出现了丙氨酸氨基转移酶(ALT)升高伴黄疸,但在泼尼松龙逐渐减量和肝脏支持治疗后,HCV RNA 和 ALT 水平逐渐下降。然后,她接受了索非布韦/雷迪帕韦的抗病毒治疗。尽管在治疗后 4 周 HCV 复发,但使用 glecaprevir/pibrentasvir 的第二次治疗取得了成功。该病例提示,即使在类固醇单药治疗后也可能发生伴有肝炎发作的 HCVr,我们在为丙型肝炎慢性感染患者使用泼尼松龙时应注意 HCVr。